StockData
Mustang Bio, Inc. logo

Mustang Bio, Inc. (MBIO) stock

MBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.35−0.02 (-4.30%)

Close on Nov 20, 2026Market cap $2.68MP/E –Yield –

Mustang Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Mustang Bio's free cash flow for the twelve months ending Dec 31, 2024 was -$11.41M. For fiscal 2024 it was -$11.41M. The highest annual figure on record is -$11.41M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$11.41M–
FY2023Dec 31, 2023-$49.54M–
FY2022Dec 31, 2022-$67.78M–
FY2021Dec 31, 2021-$57.65M–
FY2020Dec 31, 2020-$39.24M–
FY2019Dec 31, 2019-$35.93M–
FY2018Dec 31, 2018-$26.11M–
FY2017Dec 31, 2017-$13.37M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$2.00M–
Q3 FY2024Sep 30, 2024-$1.76M–
Q4 FY2023Dec 31, 2023-$7.28M–
Q3 FY2023Sep 30, 2023-$12.02M–
Q2 FY2023Jun 30, 2023-$12.43M–
Q1 FY2023Mar 31, 2023-$17.81M–
Q4 FY2022Dec 31, 2022-$15.38M–
Q3 FY2022Sep 30, 2022-$16.89M–
Q2 FY2022Jun 30, 2022-$17.88M–
Q1 FY2022Mar 31, 2022-$17.62M–
Q4 FY2021Dec 31, 2021-$16.08M–
Q3 FY2021Sep 30, 2021-$11.75M–
Q2 FY2021Jun 30, 2021-$13.79M–
Q1 FY2021Mar 31, 2021-$16.04M–
Q4 FY2020Dec 31, 2020-$10.17M–
Q3 FY2020Sep 30, 2020-$10.26M–
Q2 FY2020Jun 30, 2020-$8.13M–
Q1 FY2020Mar 31, 2020-$10.68M–
Q4 FY2019Dec 31, 2019-$10.38M–
Q3 FY2019Sep 30, 2019-$9.33M–
Q2 FY2019Jun 30, 2019-$9.43M–
Q1 FY2019Mar 31, 2019-$6.78M–
Q4 FY2018Dec 31, 2018-$6.83M–
Q3 FY2018Sep 30, 2018-$4.95M–
Q2 FY2018Jun 30, 2018-$8.10M–
Q1 FY2018Mar 31, 2018-$6.24M–
Q4 FY2017Dec 31, 2017-$5.57M–
Q3 FY2017Sep 30, 2017-$4.79M–

More Mustang Bio figures

See a number that looks wrong?